Abstract

DEVELOPMENT AND OPTIMIZATION OF GLICLAZIDE SUBLINGUAL TABLETS BY USING CO-PROCESSED EXCIPIENT TO TREAT TYPE II DIABETES

*M.Kiran Babu, Sujatha Kumari.M, MD. Rehana Sulthana, Srinivas.M, Ch.Prasanthi

Abstract

Gliclazide is a sulfonylurea antidiabetic drug approved for the treatment of type II diabetes. The objective of the work was to formulate fast disintegrating sublingual tablets of Gliclazide for the potential emergency treatment of type II diabetes. An attempt has been made to prepare fast dissolving tablets of Gliclazide using a novel coprocessed excipient (LUDIFLASH) which composes 90% mannitol, 5% kollidon CL-SF, 5% kollicoat SR 30D. Four different groups of formulations (F1, F2, F3, F4) with variation in concentration of co processed excipient and a separate formulation (F5) containing crosspovidone were prepared by direct compression method. The pre and post compression parameters were evaluated for each formulation and found to be satisfactory. The studied sublingual tablet F4 shows a lesser T50% compared to pure drug and F5 formulation. The F4 also indicates the fast dissolution and disintegration rate of the optimized Gliclazide sublingual tablet, which is prerequisite for rapid management of type II diabetes.

Keywords: .